Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry D Anderson

Showing results (81-90 of 114) with videos related to

Pageof 12
Sort By:
The Lancet. Haematology|September 14, 2023
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trialPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.
Blood|April 24, 2020
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trialPeter M Voorhees, Jonathan L Kaufman, Jacob Laubach, et al.
Transplantation and Cellular Therapy|June 4, 2024
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World ExperienceJack Khouri, Danai Dima, Hong Li, et al.
Blood Cancer Journal|August 9, 2023
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapyChristopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, et al.
Blood Cancer Journal|April 12, 2024
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy ConsortiumAimaz Afrough, Hamza Hashmi, Doris K Hansen, et al.
American Journal of Hematology|March 21, 2026
The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent MyelomaMatthew J Rees, Raffaella Cassano Cassano, Melinda Tan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2023
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
American Journal of Hematology|October 11, 2025
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-ResponseRahul Banerjee, Gurbakhash Kaur, Beatrice M Razzo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 9, 2025
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Blood Advances|October 19, 2023
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapyLauren C Peres, Laura B Oswald, Christen M Dillard, et al.
Pageof 12

Showing results (81-90 of 114) with videos related to

Sort By:
Pageof 12
The Lancet. Haematology|September 14, 2023
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trialPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.
Blood|April 24, 2020
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trialPeter M Voorhees, Jonathan L Kaufman, Jacob Laubach, et al.
Transplantation and Cellular Therapy|June 4, 2024
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World ExperienceJack Khouri, Danai Dima, Hong Li, et al.
Blood Cancer Journal|August 9, 2023
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapyChristopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, et al.
Blood Cancer Journal|April 12, 2024
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy ConsortiumAimaz Afrough, Hamza Hashmi, Doris K Hansen, et al.
American Journal of Hematology|March 21, 2026
The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent MyelomaMatthew J Rees, Raffaella Cassano Cassano, Melinda Tan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2023
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
American Journal of Hematology|October 11, 2025
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-ResponseRahul Banerjee, Gurbakhash Kaur, Beatrice M Razzo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 9, 2025
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Blood Advances|October 19, 2023
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapyLauren C Peres, Laura B Oswald, Christen M Dillard, et al.
Pageof 12